Peringatan Keamanan

Oral, mouse: LD50 = 160 mg/kg. Symptoms of overdose include nausea, vomiting, malaise, hypotension, and diaphoresis.

Tioguanine

DB00352

small molecule approved

Deskripsi

An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

Struktur Molekul 2D

Berat 167.192
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) When the compound was given in singles doses of 65 to 300 mg/m^2, the median plasma half-disappearance time was 80 minutes (range 25-240 minutes)
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)

Metabolisme

Hepatic. First converted to 6-thioguanilyic acid (TGMP). TGMP is further converted to the di- and tri-phosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP) by the same enzymes that metabolize guanine nucleotides.

Rute Eliminasi

Data eliminasi belum tersedia.

Farmakogenomik

4 Varian
TPMT (rs1800462)

The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.

TPMT (rs1800460)

The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.

TPMT (rs1142345)

The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.

TPMT (rs1800584)

The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.

Interaksi Makanan

1 Data
  • 1. Take with or without food. However, food intake may lower tioguanine serum levels.

Interaksi Obat

541 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Tioguanine.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Tioguanine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tioguanine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tioguanine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tioguanine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tioguanine.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Tioguanine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tioguanine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Tioguanine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tioguanine.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Tioguanine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tioguanine.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Tioguanine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tioguanine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tioguanine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Tioguanine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Tioguanine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Tioguanine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Tioguanine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tioguanine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Tioguanine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Tioguanine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tioguanine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tioguanine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Tioguanine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tioguanine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Tioguanine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Tioguanine.
Cladribine Tioguanine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Tioguanine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Tioguanine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Tioguanine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Tioguanine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Tioguanine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Tioguanine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Tioguanine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Tioguanine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Tioguanine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Tioguanine.
Vinorelbine The risk or severity of adverse effects can be increased when Tioguanine is combined with Vinorelbine.
Dexrazoxane The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexrazoxane.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Tioguanine is combined with Beclomethasone dipropionate.
Sorafenib The risk or severity of adverse effects can be increased when Tioguanine is combined with Sorafenib.
Streptozocin The risk or severity of adverse effects can be increased when Tioguanine is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Tioguanine is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Tioguanine is combined with Gemcitabine.
Betamethasone The risk or severity of adverse effects can be increased when Tioguanine is combined with Betamethasone.
Teniposide The risk or severity of adverse effects can be increased when Tioguanine is combined with Teniposide.
Epirubicin The risk or severity of adverse effects can be increased when Tioguanine is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Tioguanine is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Tioguanine is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Tioguanine is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Tioguanine is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Tioguanine is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Tioguanine is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Tioguanine is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Tioguanine is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Tioguanine is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Tioguanine is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Tioguanine is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Tioguanine is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Tioguanine is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Tioguanine is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Tioguanine is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Tioguanine is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Tioguanine is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Tioguanine is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Tioguanine is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Tioguanine is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Tioguanine is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Tioguanine is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Tioguanine is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Tioguanine is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Tioguanine is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Tioguanine is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Tioguanine is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Tioguanine is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Tioguanine is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Tioguanine is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Tioguanine is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Tioguanine is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Tioguanine is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Tioguanine is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Tioguanine is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Tioguanine is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Tioguanine is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Tioguanine is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Tioguanine is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Tioguanine is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Tioguanine is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Tioguanine is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Tioguanine is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Tioguanine is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Tioguanine is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Tioguanine is combined with Melphalan.

Target Protein

DNA

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 5 • International brands: 2
Produk
  • Lanvis
    Tablet • 40 mg • Oral • Canada • Approved
  • Tabloid
    Tablet • 40 mg/1 • Oral • US • Approved
  • Tabloid
    Tablet • 40 mg/1 • Oral • US • Approved
  • Tabloid
    Tablet • 40 mg/1 • Oral • US • Approved
  • Tabloid
    Tablet • 40 mg/1 • Oral • US • Approved
International Brands
  • Tioguanina — Induquimica
  • Tioguanine — IFET

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul